Production of Gas Bubbles in Reduced Gravity Environments

In a wide variety of applications such as waste water treatment, biological reactors, gas-liquid reactors, blood oxygenation, purification of liquids, etc., it is necessary to produce small bubbles in liquids. Since gravity plays an essential role in currently available techniques, the adaptation of these applications to space requires the development of new tools. Under normal gravity, bubbles are typically generated by forcing gas through an orifice in a liquid. When a growing bubble becomes large enough, the buoyancy dominates the surface tension force causing it to detach from the orifice. In space, the process is quite different and the bubble may remain attached to the orifice indefinitely. The most practical approach to simulating gravity seems to be imposing an ambient flow to force bubbles out of the orifice. In this paper, we are interested in the effect of an imposed flow in 0 and 1 g. Specifically, we investigate the process of bubble formation subject to a parallel and a cross flow. In the case of parallel flow, we have a hypodermic needle in a tube from which bubbles can be produced. On the other hand, the cross flow condition is established by forcing bubbles through an orifice on a wall in a shear flow. The first series of experiments have been performed under normal gravity conditions and the working fluid was water. A high quality microgravity facility has been used for the second type and silicone oil is used as the host liquid

Design and baseline characteristics of the finerenone in reducing cardiovascular mortality and morbidity in diabetic kidney disease trial

Background: Among people with diabetes, those with kidney disease have exceptionally high rates of cardiovascular (CV) morbidity and mortality and progression of their underlying kidney disease. Finerenone is a novel, nonsteroidal, selective mineralocorticoid receptor antagonist that has shown to reduce albuminuria in type 2 diabetes (T2D) patients with chronic kidney disease (CKD) while revealing only a low risk of hyperkalemia. However, the effect of finerenone on CV and renal outcomes has not yet been investigated in long-term trials. Patients and Methods: The Finerenone in Reducing CV Mortality and Morbidity in Diabetic Kidney Disease (FIGARO-DKD) trial aims to assess the efficacy and safety of finerenone compared to placebo at reducing clinically important CV and renal outcomes in T2D patients with CKD. FIGARO-DKD is a randomized, double-blind, placebo-controlled, parallel-group, event-driven trial running in 47 countries with an expected duration of approximately 6 years. FIGARO-DKD randomized 7,437 patients with an estimated glomerular filtration rate >= 25 mL/min/1.73 m(2) and albuminuria (urinary albumin-to-creatinine ratio >= 30 to <= 5,000 mg/g). The study has at least 90% power to detect a 20% reduction in the risk of the primary outcome (overall two-sided significance level alpha = 0.05), the composite of time to first occurrence of CV death, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for heart failure. Conclusions: FIGARO-DKD will determine whether an optimally treated cohort of T2D patients with CKD at high risk of CV and renal events will experience cardiorenal benefits with the addition of finerenone to their treatment regimen. Trial Registration: EudraCT number: 2015-000950-39; ClinicalTrials.gov identifier: NCT02545049